Global leader in imaging diagnostics selects clinivation to advance multinational market access initiatives.
NATICK, MA – April 2, 2010 – Clinivation, Inc. is pleased to announce today that Bracco Diagnostics has selected clinivation to advance certain multinational market access initiatives.
Ever-proliferating and changing global regulations generate complex challenges of execution in global market clearance operations.
Clinivation’s experienced Technology-Enabled CRO Services team understands how to approach and overcome complex development, quality, regulatory, and market access hurdles.
Unlike traditional consulting, Technology-Enabled CRO Services can employ domain-specific information technology to achieve a high operational tempo and an operational fluidity that advances to milestones and deliverables with quality and efficiency.
Quotes & Commentary:
“We look forward working with the Bracco Diagnostics teams around the world and in the U.S., and advancing the multinational market access initiatives,” said clinivation Founder and CEO Joseph Kozikowski, M.D.
For more information on the clinivation’s Technology-Enabled CRO Services, please visit the clinivation CRO Services homepage
For more information on the clinivation Enterprise Solution for Global Market Clearance Management, please visit the clinivation Global homepage.
For more information on the clinivation Enterprise Solution for On-Demand Global Regulatory Intelligence, please visit the clinivation WorldView homepage.
About Bracco Diagnostics:
Bracco Diagnostics Inc., the U.S.-based subsidiary of Bracco Imaging SpA, develops and markets imaging agents for use in X-ray, Computed Tomography, Nuclear Medicine, and Magnetic Resonance Imaging in the U.S. and Canada.
Our leading products represent a significant share of the U.S. diagnostic contrast media market.
With headquarters in Monroe Township, NJ, the company is also developing contrast agents for ultrasound procedures.